A Phase Ⅰ Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified NK Cells Targeting CD19 in Patients With Recurrent or Refractory CD19 Positive Acute Lymphoblastic Leukemia

Shanghai Simnova Biotechnology Co.,Ltd.1 个研究点分布在 1 个国家目标入组 2 人开始时间: 2022年7月21日最近更新: 2022年11月28日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: Shanghai Simnova Biotechnology Co.,Ltd.
入组人数: 2
试验地点: 1
主要终点: Safety of CAR NK-CD19 Cell

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a single arm clinical study to observe the safety ，dose tolerance and pharmacokinetic characteristics of CAR NK-CD19 in patients with recurrent or refractory CD19 positive acute lymphoblastic leukemia, and preliminarily evaluate the effectiveness, the immunogenicity of the product and the correlation between the changes of cytokines after infusion and CRS , ICANS.

详细描述

It is planned to select 9-21 patients with recurrent or refractory CD19 positive acute lymphoblastic leukemia （ALL）, from the lowest dose group. It is expected that 3-6 cases will be enrolled in each dose group. The protocol will be performed into screening period (-30~-10 days), prophase of lymophodepletion (-10~-5 days), Lymophodepletion (-5~-3 days), pre-infusion evaluation (-2~-1 days), infusion (day 0), and follow-up period (1-720 days). The incidence of DLT is observed after infusion. There are three preset dose groups in this clinical trial. The initial dose is 1.0 × 107 CAR positive NK cells/kg (body weight). Subsequent dose groups included 2.0 × 107 and 3.0 × 107 CAR positive NK cells/kg (body weight). The specific dose is determined by SRC based on the patient safety data and PK data. The maximum sample size of this study is tentatively 21 cases.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 3 Years 至 —（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥12 years in the single-dose exploration phase, age ≥3 years in the dose exploration phase, both sexes;
•Meet the diagnostic criteria for recurrent or refractory CD19 positive acute lymphoblastic leukemia.
•The main organs have good organ function.
•The estimated survival time is ≥12 weeks.
•Blood pregnancy tests for women of childbearing age are negative.
•The patient himself/herself , and/or his/her legal guardian, agree to participate in the trial and sign the informed consent form.

排除标准

•Central nervous system involvement；
•Simple extramedullary leukemia or simple extramedullary recurrence；
•Received hematopoietic stem cell transplantation within the last 3 months and had graft-versus-host disease (GVHD) in the last 2 weeks, requiring immunosuppressive agents；
•Treated with high-dose corticosteroids in the last 1 week；
•Allogeneic cell therapy, major surgery, and live or attenuated vaccine had been received within 4 weeks prior to CAR NK-CD19 infusion；
•Had received other antitumor therapy or had an uncontrolled infection within 2 weeks prior to CAR NK-CD19 infusion；
•Systemic steroids were used within 3 days before CAR NK-CD19 infusion；
•Toxicity caused by previous treatment do not fully recover or do not stabilize to grade 1；
•Concomitant autoimmune diseases, central nervous system diseases, other active malignancies, infectious diseases, severe cardiovascular diseases, etc；
•Known allergies to study drugs or drugs that may be used in the study；
•Other conditions determined by Investigator which are not suitable for participation in the study

结局指标

主要结局

Safety of CAR NK-CD19 Cell

时间窗: Up to 3 months after cell infusion

Incidence of adverse events associated with CAR NK-CD19 treatment, abnormal clinically significant laboratory findings, including dose-limiting toxicity (DLT) and maximum-tolerated Dose (MTD).

Cell count of CAR NK-CD19